Selected research
Industry Research
Digital Dyslipidemia Management Industry Research Report 2026
Market perspective
The global Digital Dyslipidemia Management market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Digital Dyslipidemia Management market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Digital Dyslipidemia Management market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Digital Dyslipidemia Management market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Digital Dyslipidemia Management include Welldoc, Lark Health, Abbott Laboratories, Roche Diabetes Care, Novartis Digital Health, AstraZeneca Digital Health, Oviva AG, Kaia Health and CureApp Inc, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Digital Dyslipidemia Management market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Digital Dyslipidemia Management.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Digital Dyslipidemia Management Market by Company
Welldoc
Lark Health
Abbott Laboratories
Roche Diabetes Care
Novartis Digital Health
AstraZeneca Digital Health
Oviva AG
Kaia Health
CureApp Inc
Welby Inc
Ping An Healthcare
Alibaba Health
Teladoc Health
Omada Health
Vida Health
Digital Dyslipidemia Management Segment by Type
Management of Hypercholesterolemia
Management of Hypertriglyceridemia
Management of Low HDL Cholesterol
Others
Digital Dyslipidemia Management Segment by Application
Personal Health Management
Hospital-Based Chronic Disease Management
Specialized Cardiovascular Care Management
Corporate Employee Health Management
Insurance-Based Health Management
Others
Digital Dyslipidemia Management Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Digital Dyslipidemia Management market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Digital Dyslipidemia Management and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Digital Dyslipidemia Management.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Digital Dyslipidemia Management companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Management of Hypercholesterolemia
- Management of Hypertriglyceridemia
- Management of Low HDL Cholesterol
- Others
Applications
- Personal Health Management
- Hospital-Based Chronic Disease Management
- Specialized Cardiovascular Care Management
- Corporate Employee Health Management
- Insurance-Based Health Management
- Others
Companies covered
- Welldoc
- Lark Health
- Abbott Laboratories
- Roche Diabetes Care
- Novartis Digital Health
- AstraZeneca Digital Health
- Oviva AG
- Kaia Health
- CureApp Inc
- Welby Inc
- Ping An Healthcare
- Alibaba Health
- Teladoc Health
- Omada Health
- Vida Health
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Digital Dyslipidemia Management by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Management of Hypercholesterolemia
- 2.2.3 Management of Hypertriglyceridemia
- 2.2.4 Management of Low HDL Cholesterol
- 2.2.5 Others
- 2.3 Digital Dyslipidemia Management by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Personal Health Management
- 2.3.3 Hospital-Based Chronic Disease Management
- 2.3.4 Specialized Cardiovascular Care Management
- 2.3.5 Corporate Employee Health Management
- 2.3.6 Insurance-Based Health Management
- 2.3.7 Others
- 2.4 Assumptions and Limitations
3 Digital Dyslipidemia Management Breakdown Data by Type
- 3.1 Global Digital Dyslipidemia Management Historic Market Size by Type (2021-2026)
- 3.2 Global Digital Dyslipidemia Management Forecasted Market Size by Type (2027-2032)
4 Digital Dyslipidemia Management Breakdown Data by Application
- 4.1 Global Digital Dyslipidemia Management Historic Market Size by Application (2021-2026)
- 4.2 Global Digital Dyslipidemia Management Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Digital Dyslipidemia Management Market Perspective (2021-2032)
- 5.2 Global Digital Dyslipidemia Management Growth Trends by Region
- 5.2.1 Global Digital Dyslipidemia Management Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Digital Dyslipidemia Management Historic Market Size by Region (2021-2026)
- 5.2.3 Digital Dyslipidemia Management Forecasted Market Size by Region (2027-2032)
- 5.3 Digital Dyslipidemia Management Market Dynamics
- 5.3.1 Digital Dyslipidemia Management Industry Trends
- 5.3.2 Digital Dyslipidemia Management Market Drivers
- 5.3.3 Digital Dyslipidemia Management Market Challenges
- 5.3.4 Digital Dyslipidemia Management Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Digital Dyslipidemia Management Players by Revenue
- 6.1.1 Global Top Digital Dyslipidemia Management Players by Revenue (2021-2026)
- 6.1.2 Global Digital Dyslipidemia Management Revenue Market Share by Players (2021-2026)
- 6.2 Global Digital Dyslipidemia Management Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Digital Dyslipidemia Management Head Office and Area Served
- 6.4 Global Digital Dyslipidemia Management Players, Product Type & Application
- 6.5 Global Digital Dyslipidemia Management Manufacturers Established Date
- 6.6 Global Digital Dyslipidemia Management Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Digital Dyslipidemia Management Market Size (2021-2032)
- 7.2 North America Digital Dyslipidemia Management Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Digital Dyslipidemia Management Market Size by Country (2021-2026)
- 7.4 North America Digital Dyslipidemia Management Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Digital Dyslipidemia Management Market Size (2021-2032)
- 8.2 Europe Digital Dyslipidemia Management Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Digital Dyslipidemia Management Market Size by Country (2021-2026)
- 8.4 Europe Digital Dyslipidemia Management Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Digital Dyslipidemia Management Market Size (2021-2032)
- 9.2 Asia-Pacific Digital Dyslipidemia Management Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Digital Dyslipidemia Management Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Digital Dyslipidemia Management Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Digital Dyslipidemia Management Market Size (2021-2032)
- 10.2 South America Digital Dyslipidemia Management Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Digital Dyslipidemia Management Market Size by Country (2021-2026)
- 10.4 South America Digital Dyslipidemia Management Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Digital Dyslipidemia Management Market Size (2021-2032)
- 11.2 Middle East & Africa Digital Dyslipidemia Management Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Digital Dyslipidemia Management Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Digital Dyslipidemia Management Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Welldoc
- 12.1.1 Welldoc Company Information
- 12.1.2 Welldoc Business Overview
- 12.1.3 Welldoc Revenue in Digital Dyslipidemia Management Business (2021-2026)
- 12.1.4 Welldoc Digital Dyslipidemia Management Product Portfolio
- 12.1.5 Welldoc Recent Developments
- 12.2 Lark Health
- 12.2.1 Lark Health Company Information
- 12.2.2 Lark Health Business Overview
- 12.2.3 Lark Health Revenue in Digital Dyslipidemia Management Business (2021-2026)
- 12.2.4 Lark Health Digital Dyslipidemia Management Product Portfolio
- 12.2.5 Lark Health Recent Developments
- 12.3 Abbott Laboratories
- 12.3.1 Abbott Laboratories Company Information
- 12.3.2 Abbott Laboratories Business Overview
- 12.3.3 Abbott Laboratories Revenue in Digital Dyslipidemia Management Business (2021-2026)
- 12.3.4 Abbott Laboratories Digital Dyslipidemia Management Product Portfolio
- 12.3.5 Abbott Laboratories Recent Developments
- 12.4 Roche Diabetes Care
- 12.4.1 Roche Diabetes Care Company Information
- 12.4.2 Roche Diabetes Care Business Overview
- 12.4.3 Roche Diabetes Care Revenue in Digital Dyslipidemia Management Business (2021-2026)
- 12.4.4 Roche Diabetes Care Digital Dyslipidemia Management Product Portfolio
- 12.4.5 Roche Diabetes Care Recent Developments
- 12.5 Novartis Digital Health
- 12.5.1 Novartis Digital Health Company Information
- 12.5.2 Novartis Digital Health Business Overview
- 12.5.3 Novartis Digital Health Revenue in Digital Dyslipidemia Management Business (2021-2026)
- 12.5.4 Novartis Digital Health Digital Dyslipidemia Management Product Portfolio
- 12.5.5 Novartis Digital Health Recent Developments
- 12.6 AstraZeneca Digital Health
- 12.6.1 AstraZeneca Digital Health Company Information
- 12.6.2 AstraZeneca Digital Health Business Overview
- 12.6.3 AstraZeneca Digital Health Revenue in Digital Dyslipidemia Management Business (2021-2026)
- 12.6.4 AstraZeneca Digital Health Digital Dyslipidemia Management Product Portfolio
- 12.6.5 AstraZeneca Digital Health Recent Developments
- 12.7 Oviva AG
- 12.7.1 Oviva AG Company Information
- 12.7.2 Oviva AG Business Overview
- 12.7.3 Oviva AG Revenue in Digital Dyslipidemia Management Business (2021-2026)
- 12.7.4 Oviva AG Digital Dyslipidemia Management Product Portfolio
- 12.7.5 Oviva AG Recent Developments
- 12.8 Kaia Health
- 12.8.1 Kaia Health Company Information
- 12.8.2 Kaia Health Business Overview
- 12.8.3 Kaia Health Revenue in Digital Dyslipidemia Management Business (2021-2026)
- 12.8.4 Kaia Health Digital Dyslipidemia Management Product Portfolio
- 12.8.5 Kaia Health Recent Developments
- 12.9 CureApp Inc
- 12.9.1 CureApp Inc Company Information
- 12.9.2 CureApp Inc Business Overview
- 12.9.3 CureApp Inc Revenue in Digital Dyslipidemia Management Business (2021-2026)
- 12.9.4 CureApp Inc Digital Dyslipidemia Management Product Portfolio
- 12.9.5 CureApp Inc Recent Developments
- 12.10 Welby Inc
- 12.10.1 Welby Inc Company Information
- 12.10.2 Welby Inc Business Overview
- 12.10.3 Welby Inc Revenue in Digital Dyslipidemia Management Business (2021-2026)
- 12.10.4 Welby Inc Digital Dyslipidemia Management Product Portfolio
- 12.10.5 Welby Inc Recent Developments
- 12.11 Ping An Healthcare
- 12.11.1 Ping An Healthcare Company Information
- 12.11.2 Ping An Healthcare Business Overview
- 12.11.3 Ping An Healthcare Revenue in Digital Dyslipidemia Management Business (2021-2026)
- 12.11.4 Ping An Healthcare Digital Dyslipidemia Management Product Portfolio
- 12.11.5 Ping An Healthcare Recent Developments
- 12.12 Alibaba Health
- 12.12.1 Alibaba Health Company Information
- 12.12.2 Alibaba Health Business Overview
- 12.12.3 Alibaba Health Revenue in Digital Dyslipidemia Management Business (2021-2026)
- 12.12.4 Alibaba Health Digital Dyslipidemia Management Product Portfolio
- 12.12.5 Alibaba Health Recent Developments
- 12.13 Teladoc Health
- 12.13.1 Teladoc Health Company Information
- 12.13.2 Teladoc Health Business Overview
- 12.13.3 Teladoc Health Revenue in Digital Dyslipidemia Management Business (2021-2026)
- 12.13.4 Teladoc Health Digital Dyslipidemia Management Product Portfolio
- 12.13.5 Teladoc Health Recent Developments
- 12.14 Omada Health
- 12.14.1 Omada Health Company Information
- 12.14.2 Omada Health Business Overview
- 12.14.3 Omada Health Revenue in Digital Dyslipidemia Management Business (2021-2026)
- 12.14.4 Omada Health Digital Dyslipidemia Management Product Portfolio
- 12.14.5 Omada Health Recent Developments
- 12.15 Vida Health
- 12.15.1 Vida Health Company Information
- 12.15.2 Vida Health Business Overview
- 12.15.3 Vida Health Revenue in Digital Dyslipidemia Management Business (2021-2026)
- 12.15.4 Vida Health Digital Dyslipidemia Management Product Portfolio
- 12.15.5 Vida Health Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst